Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling.

New-onset post-transplantation diabetes mellitus (PTDM) occurs commonly after allogeneic hematopoietic cell transplantation (HCT) and is associated with inferior survival. We hypothesize that PTDM and nonrelapse mortality (NRM) are related to IL-33/suppression of tumorigenicity 2 (ST2) signaling and that soluble ST2 (sST2) levels will predict PTDM diagnosis. sST2 was measured at engraftment and day +30 in 36 euglycemic HCT recipients followed prospectively for PTDM (cohort 1). Results were confirmed in a validation cohort of 26 patients without pre-existing diabetes analyzed retrospectively for PTDM (cohort 2). Twelve patients with established diabetes before HCT were analyzed in cohort 3. When compared with recipients without PTDM, patients developing PTDM (n = 24) from cohort 1 had elevated sST2 levels at engraftment (P = .02) and at day +30 (P < .01). Cohort 2 confirmed this finding at engraftment (P = .01). Cohort 3 patients with pretransplantation diabetes had higher sST2 at engraftment than patients maintaining euglycemia after HCT from cohort 2 (P = .03). Multivariate analysis of cohorts 1 and 2 showed high engraftment sST2 predicted increased PTDM and NRM risk, independent of conditioning and grades 3 to 4 acute graft-versus-host-disease. sST2 was elevated in PTDM, indicating a relationship between glucose homeostasis and the IL-33/ST2 axis after transplantation. Correction of metabolic complications may decrease sST2 and improve NRM.

• Publication year

  2017

• Venue

  Biology of Blood and Marrow Transplantation

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bbmt.2016.12.627PMID 28013014PMCID PMC5321545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease

  2015cited by this paper
• Erratum: The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue–resident regulatory T cells

  2015cited by this paper
• The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.

  2015cited by this paper
• Depletion of Fat Tregs Prevents Age-Associated Insulin Resistance

  2015cited by this paper
• The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue–resident regulatory T cells

  2015cited by this paper
• High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.

  2015cited by this paper
• ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

  2013cited by this paper
• Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity.

  2012cited by this paper
• Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation.

  2011cited by this paper
• Normalization of obesity-associated insulin resistance through immunotherapy

  2010cited by this paper
• Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters

  2009cited by this paper
• Normalization of Obesity-Associated Insulin Resistance through Immunotherapy: CD4+ T Cells Control Glucose Homeostasis

  2009cited by this paper
• Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival

  2008cited by this paper
• Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

  2005cited by this paper
• IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE

  1997cited by this paper
• 1994 Consensus Conference on Acute GVHD Grading.

  1995cited by this paper

• The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party

  2023cites this paper
• General Rehabilitation Program after Knee or Hip Replacement Significantly Influences Erythrocytes Oxidative Stress Markers and Serum ST2 Levels

  2022cites this paper
• Pre-Transplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation.

  2022cites this paper
• Early high plasma ST2, the decoy IL-33 receptor, in children undergoing hematopoietic cell transplantation is associated with the development of post-transplant diabetes mellitus

  2020cites this paper
• Post‐haematopoietic cell transplantation outcomes: why ST2 became a ‘golden nugget’ biomarker

  2020cites this paper
• Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)

  2020cites this paper
• New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide

  2020cites this paper
• Challenging and opportunities in clinical implementation of circulating cardiac biomarkers in diabetes mellitus: the narrative review

  2020cites this paper
• Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers.

  2019cites this paper
• Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation.

  2019cites this paper
• New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications.

  2019cites this paper
• ST2/MYD88 signaling is a therapeutic target alleviating murine acute graft-versus-host disease sparing T regulatory cell function

  2018cites this paper
• Biomarkers for posttransplantation outcomes.

  2018cites this paper
• Clinical Proteomics for Post‐Hematopoeitic Stem Cell Transplantation Outcomes

  2018cites this paper
• The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases

  2017influential citation
• Clinical impact of hyperglycemia on days 0–7 after allogeneic stem cell transplantation

  2017cites this paper